Palbociclib s1116

LN428 and LN308 were previously established from human GBM samples [23 (link)]. The human lung cancer cell line A549 and human breast cancer cell line MDA-MB-231 were obtained from ATCC (Cat. # CCL-185 and HTB-26). All cell lines were cultured in DMEM medium (Corning, 10013CV) supplemented with 10% fetal bovine serum (sigma, F0926),1% penicillin and 1% streptomycin, at 37°C with 5% CO₂ supplementation. Clinical grade ribociclib (LEE011) was obtained from Novartis, Inc. Carmustine (C0400), carboplatin (C2538), temozolomide (T2577), etoposide (E1383), irinotecan (I1406) were from Sigma-Aldrich; paclitaxel or taxol (S1150) and palbociclib (S1116) were from Selleck Chemicals.

Palbociclib (S1116) and Abemaciclib (S7158) were purchased from Selleck Chemicals (Houston, Texas, USA). Antibodies against HSP90 (H-114), cyclin D1 (A12), CDK6 (C-21), CDK4 (DCS-35), p16 (C-20), p21 (H164), cyclin E (HE12), c-Jun (G4) and c-Fos (E8) were from Santa Cruz Biotechnology; antibodies against cyclin D2 (D52F9) and p-RB (S795) were from Cell Signaling; antibody against SMARCA4 were from Bethyl Laboratories (A300-813A). Antibody against Rb (554136) was from BD Pharmingen. Cyclin D3 (ab28283) antibody was from Abcam. Antibody against SMARCA4 was used with 1:5000 dilution and all others with 1:1000 dilution. Antibodies for IHC and ChIP are listed in the corresponding method section below.